Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 1.00 |
| ▸ | SLC28A2 | O43868 | 1/20 | 1.00 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 1.00 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 1.00 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.69 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.65 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.63 |
| ▸ | P2RY14 | Q15391 | 7/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Uridine SCHEMBL2114452 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL16273806 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL4455604 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL2912983 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL890304 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL9945547 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL2056530 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL2056634 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL20987631 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL8590899 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025080839-A1 | IMPROVED RADIOSYNTHESIS OF 18F-LABELED NUCLEOSIDE ANALOGUES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2025-04-17 | — | — | WO | claimed |
| US-20230416293-A1 | SYNTHESIS OF [18F]-LABELED THYMIDINE ANALOGUES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2023-12-28 | — | — | US | claimed |
| WO-2022109244-A1 | SYNTHESIS OF [18F] -LABELED THYMIDINE ANALOGUES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2022-05-27 | — | — | WO | claimed |
| CN-105246337-B | Thymidine Kinase Diagnostic Assays for Gene Therapy Applications | 吉恩维沃公司 | 2019-02-15 | — | — | CN | claimed |
| EP-2603516-A2 | SYNTHESIS OF 2'-DEOXY-2'-[18F]FLUORO-5-METHYL-1-B-D-ARABINOFURANOSYLURACIL (18F-FMAU) | University of Southern California (US) | 2013-06-19 | — | — | EP | claimed |
| WO-2012009666-A2 | SYNTHESIS OF 2'-DEOXY-2'-[18F]FLUORO-5-METHYL-1-B-D-ARABINOFURANOSYLURACIL (18F-FMAU) | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2012-01-19 | — | — | WO | claimed |
| EP-1835035-B1 | A process for immobilizing cells on a resin | EXPLORA LAB SA (CH) | 2010-02-17 | — | — | EP | claimed |
| EP-2009990-A2 | METHODS AND COMPOSITIONS RELATED TO ADENOASSOCIATED VIRUS-PHAGE PARTICLES | The Board of Regents of The University of Texas System (US) | 2009-01-07 | — | — | EP | claimed |
| EP-1992632-A1 | Method for the synthesis of cyclouridine | EXPLORA Laboratories SA (CH) | 2008-11-19 | — | — | EP | claimed |
| US-20070249023-A1 | Process for immobilizing cells on a resin | EXPLORA LABORATORIES S.A. (CH) | 2007-10-25 | — | — | US | claimed |
| WO-2007118245-A2 | METHODS AND COMPOSITIONS RELATED TO ADENOASSOCIATED VIRUS-PHAGE PARTICLES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2007-10-18 | — | — | WO | claimed |
| EP-1835035-A1 | A process for immobilizing cells on a resin | EXPLORA Laboratories SA (CH) | 2007-09-19 | — | — | EP | claimed |
| WO-1996028190-A1 | NON-INVASIVE IMAGING OF GENE TRANSFER | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1996-09-19 | — | — | WO | claimed |
| WO-2025080839-A1 | IMPROVED RADIOSYNTHESIS OF 18F-LABELED NUCLEOSIDE ANALOGUES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2025-04-17 | — | — | WO | disclosed |
| CN-118837454-A | Coronary atherosclerosis grading diagnosis biomarker based on plasma metabolome and application thereof | 江南大学 | 2024-10-25 | — | — | CN | disclosed |
| CN-114630911-B | Enzymatic process for the preparation of UDP-GlcNAc | 马克斯·普朗克科学促进学会 | 2024-06-28 | — | — | CN | disclosed |
| WO-1990015064-A1 | THERAPEUTIC NUCLEOSIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-12-13 | — | — | WO | disclosed |
| EP-0044085-B1 | NOVEL NUCLEOSIDE DERIVATIVES | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1983-05-25 | — | — | EP | disclosed |
| US-4367332-A | N4 -Alkoxycarbonylarabinofuranosylcytosine | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1983-01-04 | — | — | US | disclosed |
| EP-0044085-A1 | Novel nucleoside derivatives | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1982-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416293-A1 | SYNTHESIS OF [18F]-LABELED THYMIDINE ANALOGUES | DCTD, DUT, RNMT | SLC28A1 33/4885SLC28A2 38/4885SLC29A1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.